Clinical Trials Logo

Clinical Trial Summary

The primary purpose of the study is to evaluate a standardized method of screening for platelet signalling defects in patients with constitutional disorders of platelet function of unknown origin. We hypothesize that such defects are under-diagnosed in patients, due to heavy workup and requirement of relatively large blood sample by conventional biochemical methods. We propose to analyse kinase signalling downstream platelet membrane receptors using multiplex flow cytometry quantification and fluorescent platelet barcoding.


Clinical Trial Description

Little is known of the molecular basis of disorders of signalling pathways potentially responsible of constitutional defects of platelet functions (adhesion, aggregation or secretion) (1-5). Indeed, in routine practice, this investigation is limited by the complexity of the analyse using biochemical methods (western blotting), and the requirement of large amount of platelets.

We have designed a new approach for the quantification of platelet cytoplasmic phosphoproteins by flow cytometry. Fresh platelets in platelet rich plasma are analysed at baseline or after stimulation by major agonists (ADP, TRAP, thromboxane analogue, or collagen-related peptide), with and without relevant inhibitors of each pathway. Multiplex barcoding is used to identify each condition, allowing a high throughput analysis (6, 7). Platelet signalling profiling of Akt, Slp76, P38 MAPK and LIMK can be obtained from a blood sample of less than 10 ml, and within 6h The main objective of the study is to standardize the method between clinical laboratories with a standard expertise in flow cytometry. The study will be performed in 4 academic hospitals members of the French reference network of rare platelet diseases. Three groups of patients referred for mild or severe bleeding disorders will be included: 1) a control group of patients (30 per centre) with a bleeding disorder definitely other than of platelet origin (e.g. "low" von Willebrand); 2) a group of 10 patients per centre with definite constitutional platelet disorder (e.g. Glanzmann thrombasthenia) and 3) a group of 10 patients per centre with a defect of platelet function of unknown origin, potentially defective in signalling pathway.

The control group will serve to standardize the method between centres and to establish the reference values. A quality control will be set up by using frozen platelet preparations. The patients with definite platelet disorder will be useful for detecting potential signalling defects still not described in these pathologies. Platelet signalling defects which could be evidenced in these groups will be further identified by conventional biochemical and molecular methods after confirmation on a new sample.

If this new approach can be proposed to clinical laboratories working on rare platelet diseases, we expect an advance in our knowledge in the field. In addition the method has a potential in pharmaceutical innovation, for identifying (8) or monitoring new antiplatelet agents (9, 10), or identifying platelet defects induced by new "target therapies" designed for other diseases such as cancer or immune pathologies (10). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01957345
Study type Interventional
Source University Hospital, Toulouse
Contact
Status Completed
Phase N/A
Start date February 2013
Completion date June 29, 2017

See also
  Status Clinical Trial Phase
Completed NCT04554901 - The Effect of Cocoa on Platelet Function Profiles in Patients N/A
Completed NCT03621020 - Clinical Performance Evaluation of T-TAS 01 PL Chip
Completed NCT03667066 - clOpidogrel "resIstaNce" in a Selected Population of Patients at a Tertiary Cardiovascular Center in Trinidad
Recruiting NCT05588011 - Influence of Oxygenator Selection on Platelet Function and Rotational Thromboelastometry Following Cardiopulmonary Bypass N/A
Completed NCT01454427 - Influence of Anesthesia Drugs on Impedance Aggregometry N/A
Completed NCT03188705 - CES1 Carriers in the PAPI Study Phase 4
Recruiting NCT03583229 - Coronary Artery Disease After Heart Transplantation N/A
Recruiting NCT05730114 - Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
Completed NCT03182946 - Correcting Platelet Dysfunction After Traumatic Brain Injury
Completed NCT05033236 - Platelets and Complement Activation in Coronary Artery Bypass Graft Surgery (CABG)
Recruiting NCT04419948 - Oleocanthal Rich Olive Oil Acute Effects on Hyperglycemia and Platelet Activation in T2DM N/A
Completed NCT04400760 - The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts. Phase 2/Phase 3
Completed NCT03458351 - RIPC and Platelet Activation on Platelet Activation During Cardiopulmonary Bypass N/A
Completed NCT02368730 - Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures N/A
Not yet recruiting NCT04876573 - Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19 Phase 2
Completed NCT04734028 - PTRG-DES Consortium
Completed NCT01382134 - Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction N/A
Completed NCT03028064 - Point of Care Testing of Platelet Function in Patients With Acute Upper Gastrointestinal Bleeding
Completed NCT05237492 - The Influence of Tramadol on Platelet Function Phase 4
Completed NCT03049566 - Low-dose Acetylsalicylic Acid Before Non-cardiac Surgery N/A